Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04222062 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 2027 to Dec 2028 Completion date: Dec 2028 to Dec 2029v14 Show 1 more changeShow less
    • Completion date: Dec 2028 to Dec 2029
  2. Primary completion date: Dec 2025 to Dec 2027 Completion date: Dec 2026 to Dec 2028 · Eligibility criteria expanded, about 85 words · Study description expanded, about 3 wordsv13 Show 3 more changesShow less
    • Completion date: Dec 2026 to Dec 2028
    • Eligibility criteria expanded, about 85 words
    • Study description expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites: 3 to 2v12
  4. Primary completion date: Dec 1, 2025 to Dec 2025 Completion date: Dec 1, 2026 to Dec 2026v11 Show 1 more changeShow less
    • Completion date: Dec 1, 2026 to Dec 2026
  5. Re-verified, no change to tracked fieldsv10
Show 8 earlier versionsHide 8 earlier versions
  1. Lead sponsor: Michele Aizenberg, MD to University of Nebraska Site contacts updated at 1 of 3 sitesv9 Show 1 more changeShow less
    • Site contacts updated at 1 of 3 sites
  2. Re-verified, no change to tracked fieldsv8
  3. Study sites: 1 to 3 Eligibility criteria shortened, about 46 wordsv7 Show 1 more changeShow less
    • Eligibility criteria shortened, about 46 words

    See this version in full on ClinicalTrials.gov ↗

  4. Primary completion date: Nov 1, 2025 to Dec 1, 2025 Completion date: Nov 1, 2026 to Dec 1, 2026v6 Show 1 more changeShow less
    • Completion date: Nov 1, 2026 to Dec 1, 2026
  5. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Nov 1, 2020 to Nov 6, 2020 · Site details revisedv5 Show 2 more changesShow less
    • Start date changed from estimate of Nov 1, 2020 to Nov 6, 2020
    • Site details revised
  6. Start date: Oct 1, 2020 to Nov 1, 2020 Primary completion date: Oct 1, 2025 to Nov 1, 2025 · Completion date: Oct 1, 2026 to Nov 1, 2026v4 Show 2 more changesShow less
    • Primary completion date: Oct 1, 2025 to Nov 1, 2025
    • Completion date: Oct 1, 2026 to Nov 1, 2026
  7. Primary completion date: Feb 1, 2025 to Oct 1, 2025 Start date: Feb 1, 2020 to Oct 1, 2020 · Completion date: Feb 1, 2026 to Oct 1, 2026v3 Show 2 more changesShow less
    • Start date: Feb 1, 2020 to Oct 1, 2020
    • Completion date: Feb 1, 2026 to Oct 1, 2026
  8. Primary endpoint revisedv2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is being done to see if adding GLIADEL to the site where the tumor was removed works as well as just having the tumor removed with radiation treatment done within six weeks after the surgery to keep the cancer from coming back.
Trial Details
NCT Number NCT04222062
Lead Sponsor University of Nebraska
Collaborators: Arbor Pharmaceuticals, Inc.
Conditions Brain Tumor - Metastatic
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov